



Molecular Mechanisms in Anaphylaxis

Guest Editor:

Dr. Vanesa Esteban

1. Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, UAM, 28040 Madrid, Spain
2. Faculty of Medicine and Biomedicine, Alfonso X El Sabio University, 28691 Madrid, Spain

Deadline for manuscript submissions:

closed (30 December 2022)

Message from the Guest Editor

Anaphylaxis (AX) is the most severe manifestation of allergic disorders, being a systemic hypersensitivity life-threatening reaction that evolves rapidly. Among the most frequent triggers are food, drugs, and hymenoptera venoms. The plethora of features associated with AX confers difficulties in its diagnosis, impairing the ability to adequately treat these severe reactions. Generally, the diagnosis is carried out according to the clinical symptoms, which are common to many other pathologies, so confirmation through in vitro markers and knowledge about their molecular mechanisms is advisable. Mast cells and basophils are recognized as effector cells eliciting the anaphylactic reaction. However, many other cells and mediators are also relevant. Moreover, the release of mediators causes an endothelial barrier breakdown. This fact produces an increase in vascular permeability and a leakage of fluids, which have influence in two decisive and severe factors (hypotension and hypoxia). Thus, the primary purpose of this Special Issue is to collect scientific contributions providing novel insight into the molecular mechanisms of AX.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)